MC1568

Cat. No.：852475-26-4

CAS No. ：852475-26-4

规格

价格(RMB)

库存
5mg

￥296

In-stock
10mg

￥475

In-stock
50mg

￥1425

In-stock
100mg

￥2660

In-stock
200mg

￥2660

Inquiry
500mg

￥2660

Inquiry

查看相关靶点产品

产品资料
参考文献

产品名称:	MC1568
CAS No.:	852475-26-4
Chemical Name:
Synonyms:	MC1568;(E)-3-[4-[(E)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-N-hydroxyprop-2-enamide;MC-1568;MC1568 (MC-1568, MC 1568);(E)-3-(4-((E)-3-(3-fluorophenyl)-3-oxoprop-1-enyl)-1-methyl-1H-pyrrol-2-yl)-N-hydroxyacrylamide;MC-1568,MC1568;3-[5-(3
分子量:	314.31
分子式:	C₁₇H₁₅FN₂O₃
SMILES:	O=C(NO)/C=C/C1=CC=C(/C=C/C(C2=CC=CC(F)=C2)=O)N1C
存储:	Please store the product under the recommended conditions in theCertificate of Analysis.
运输:	Room temperature in continental US; may vary elsewhere.

Select Batch:

Purity: 0.98

de Ruijter, A.J., van Gennip, A.H., Caron, H.N., et al.Histone deacetylases (HDACs): Characterization of the classical HDAC familyBiochem J.370(Pt 3),737-749(2003)', 'Yang, X.J., and Grégoire, S.Class II histone deacetylases: From sequence to function, regulation, and clinical implicationMol. Cell. Biol.25(8),2873-2884(2005)', 'Mai, A., Massa, S., Pezzi, R., et al.Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamidesJ. Med. Chem.48(9),3344-3353(2005)', 'Mai, A., Jelicic, K., Rotili, D., et al.Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemiaMol. Pharmacol.72(5),1111-1123(2007)', 'Nebbioso, A., Manzo, F., Miceli, M., et al.Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexesEMBO reports10(7),776-782(2009)', 'Duong, V., Bret, C., Altucci, L., et al.Specific activity of class II histone deacetylases in human breast cancer cellsMol. Cancer Res.6(12),1908-1919(2008)', "Nebbioso, A., Dell'Aversana, C., Bugge, A., et al.HDACs class II-selective inhibition alters nuclear receptor-dependent differentiationJ. Mol. Endocrinol.45(4),219-228(2010)", 'Wang, G., He, J., Zhao, J., et al.Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancerPLoS One7(12),1-10(2012)', 'Mannaerts, I., Eysackers, N., Onyema, O.O., et al.Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29PLoS One8(1),1-9(2013)', 'Spallotta, F., Tardivo, S., Nanni, S., et al.Detrimental effect of class-selective histone deacetylase inhibitors during tissue regeneration following hindlimb ischemiaJ. Biol. Chem.288(32),22915-22929(2013)